Chinese Journal of Clinical Oncology

, Volume 1, Issue 1, pp 37–41 | Cite as

HBME-1, CD15 and p53 protein expression in thyroid carcinoma and their significance in diagnosis

Original Article



To investigate the protein expression of HBME-1, CD15 and p53 in thyroid carcinoma and in bengin thyroid diseases and to evaluate their value in diagnosis of thyroid disease.


Sixty-one cases of thyroid carcinoma and 27 cases of different kinds of benign thyroid diseases were studied by immunohistochemical methods.


All cases of differentiated thyroid carcinoma were positive for HBME-1, 35.7% positive for CD15 and only 14.3% positive for p53. Twenty-seven cases of benign thyroid lesions were absolutely negative for p53, 7.4% of which were CD15 positive and 25.9% of which were HBME-1 positive.


HBME-1 and CD15 may be helpful to assist differential diagnosis of thyroid carcinoma from benign thyroid diseases.


thyroid carcinoma HBME-1 CD15 p53 immunohistochemistry diagnosis 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Christopher D M Fletcher. Diagnostic histopathology of tumors, 2nd. Churchill Livingstone, 2000; 963.Google Scholar
  2. 2.
    Livolsi VA. Surgical pathology of the thyroid. WB Saunders company, 1990;131.Google Scholar
  3. 3.
    Scopa CD, Melachrinou M, Saradopoulou C, et al. The significance of the grooved nucleus in thyroid lesions. Mod Pathol, 1993; 6:691–694.PubMedGoogle Scholar
  4. 4.
    Miettinen M, Karkkainen P. Differential reactivity of HBME-1 and CD15 antibodies in benign and malignant thyroid tumors. Preferential reactivity with malignant tumours. Virchows Arch, 1996;429:213–219.PubMedCrossRefGoogle Scholar
  5. 5.
    Pollina L, Pacini F, Fontanini G, et al. bcl-2, p53 and proliferating cell nuclear antigen expression is related to the degree of differentiation in thyroid carcinomas. Br J Cancer, 1996; 73:139–143.PubMedGoogle Scholar
  6. 6.
    Kilicarslan B, Pesterelli EH, Oren N, et al. Epithelial membrane antigen and S-100 protein expression in benign and malignant papillary thyroid neoplasma. Adv Clin Path, 2000; 4:155–158.PubMedGoogle Scholar
  7. 7.
    Mai KT, Landry DC, Thomas J, et al. Follicular adenoma with papillary architecture; a lesion mimicking papillary thyroid carcinoma. Histopathology, 2001;39:25–32.PubMedCrossRefGoogle Scholar
  8. 8.
    Cheung CC, Ezzat S, Freeman JL, et al. Immunohistochemical diagnosis of papillary thyroid carcinoma. Mod Pathol, 2001;14:338–342.PubMedCrossRefGoogle Scholar
  9. 9.
    Ordonez NG. The immunohistochemical diagnosis of malignant mesothelioma. Differention of mesothelioma and lung adenocarcinoma. Am J Surg Pathol, 1989;13:276–291.PubMedGoogle Scholar
  10. 10.
    Schroder S, Schwarz W, Rehpenning W, et al. Prognostic significance of Leu-M1 immunostaining in papillary carcinomas of the thyroid gland. Virchows Arch A Pathol Anat Histopathol, 1987; 411:435–439.PubMedCrossRefGoogle Scholar
  11. 11.
    Shahedian B, Shi Y, Zou M, et al. Thyroid carcinoma is characterized by genomic instability: evidence from p53 mutations. Mol Genet Metab, 2001; 72:155–163.PubMedCrossRefGoogle Scholar
  12. 12.
    Dobashi Y, Sakamoto A, Sugimura H, et al. Over expression of p53 as a possible prognostic factor in human thyroid carcinoma. Am J Surg Pathol, 1993;17:375–381.PubMedCrossRefGoogle Scholar

Copyright information

© Chinese Anti-Cancer Association and Springer 2003

Authors and Affiliations

  1. 1.Department of PathologyHealth Science Center of Peking UniversityBeijingChina

Personalised recommendations